Vaccine Hesitancy in Patients With Multiple Sclerosis: Preparing for the SARS-CoV-2 Vaccination Challenge

Conclusion Our study demonstrated that in our single-center cohort, 41.3% of patients with MS do not get the recommended pneumococcal vaccination. Future research should focus on vaccine hesitancy in the vulnerable cohort of patients with MS to improve the safety of MS immunotherapies.

http://nn.neurology.org/cgi/content/short/8/3/e991?rss=1

Source: Neurology Neuroimmunology and Neuroinflammation - April 2, 2021 Category: Neurology Authors: Diem, L., Friedli, C., Chan, A., Salmen, A., Hoepner, R. Tags: Multiple sclerosis Article Source Type: research